Abstract

Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed?

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified?
Robert J Fontana
Gastroenterology | VOL. 130
Robert J FontanaRobert J Fontana
01 Apr 2006
New pieces to the hepatitis C treatment puzzle
Ola Weiland
Journal of Hepatology | VOL. 33
Ola WeilandOla Weiland
01 Sep 2000
Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?
Anna S Lok ... Pratima Sharma
Gastroenterology | VOL. 141
Anna S Lok, et. al.Anna S Lok ... Pratima Sharma
25 Oct 2011
Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C
Thomas Berg ... Miriam Huber
Gastroenterology | VOL. 129
Thomas Berg, et. al.Thomas Berg ... Miriam Huber
01 Aug 2005
View more papers

More From: Journal of Hepatology

Paper Title
Journal
Date
Author
In Memoriam: Valeer Desmet (1931-2024)
Tania Roskams ... Johan Fevery
Journal of Hepatology | VOL. -
Tania Roskams, et. al.Tania Roskams ... Johan Fevery
18 May 2024
Increases and decreases in liver stiffness measurements are independently associated with the risk of liver-related events in NAFLD.
Samer Gawrieh ...
Journal of hepatology | VOL. -
Samer Gawrieh, et. al.Samer Gawrieh ...
16 May 2024
Osteoporosis in hepatitis B patients receiving tenofovir disoproxil fumarate: does fibroblast growth factor 23 play a role?
Eva Van Oorschot ... Ger H Koek
Journal of Hepatology | VOL. -
Eva Van Oorschot, et. al.Eva Van Oorschot ... Ger H Koek
01 May 2024
Hepatitis B Virus spliced 1 RNA, a key factor for viral expression
Pierre Bablon ... Patrick Soussan
Journal of Hepatology | VOL. -
Pierre Bablon, et. al.Pierre Bablon ... Patrick Soussan
01 May 2024
View more papers